General

MRSA Analysis Module – Clinical Study Commenced
||
We are pleased to announce that we have commenced a clinical study to validate clinical performance of APAS Independence’s automatic analysis of MRSA.
continue reading
Breaking Into The US Market. What Does It Really Take? 
||
Our VP of Global Business Development Peter Bradley recently presented at the ANDHealth Digital Health Summit in Melbourne
continue reading
Appointment US Based Non-Executive Director: Simon Arkell
||
LBT Innovations is pleased to announce the appointment of Simon Arkell as a Non-Executive Director, starting 30th January 2019.
continue reading
FDA 510(k) submitted for APAS® Independence
||
LBT Innovations joint venture company, Clever Culture Systems submits US FDA 510(k) for APAS Independence instrument with Urine Analysis Module.
continue reading
Australian Sales Update
||
LBT Innovations provides an update on sales activities in the Australian market and previously advised expected sales of the APAS® Independence in calendar 2018.
continue reading
First Placement of APAS Independence into US Lab
||
Clever Culture Systems has placed the first APAS® Independence into a US medical centre to act as a key opinion leader ahead of US commercial launch.
continue reading
Quarterly Activities & Cashflow Report
||
We are pleased to release our Quarterly Cashflow report and Update for the quarter ended 30 September 2018 (the Quarter).
continue reading
APAS Independence wins award at MDEA
||
The APAS Independence, the product of Clever Culture Systems, has won Silver at the Medical Design Excellence Awards in New York.
continue reading
APAS Independence – MDEA award Finalist
||
The APAS Independence, the product of Clever Culture Systems, has been nominated as a finalist in the Medical Design Excellence Awards.
continue reading
Using AI to automate clinical microbiology
||
Australian Government grant initiative. Business.com.au Research and Development Tax Incentives - Customer Story on LBT Innovations
continue reading